Genomic Valley Biotech Share Price Today | Stock Price & Genomic Valley Biotech Share Screener
As of November 18, 2026, the live Genomic Valley Biotech share price (BSE: GVBL) is ₹44.70, down 0.02% from the previous close, with shares trading between ₹43.56 and ₹44.71 in today's trading session, and a 52-week range of ₹21.85–₹58.45. Track GVBL market capitalization to gauge the company's total market size. Use the Genomic Valley Biotech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Genomic Valley Biotech opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Genomic Valley Biotech Share Price Chart
Track the current stock price of Genomic Valley Biotech with an interactive chart. Analyse GVBL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Genomic Valley Biotech stock quote in one place.
The quote of ₹44.70 sits between the 52-week low of ₹21.85 and the 52-week high of ₹58.45, and the latest session moved -0.02% from the previous close.
Genomic Valley Biotech Company Profile - Fundamental Screener
Screen Genomic Valley Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GVBL shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE574D01010.
Company Details
Classification
Identifiers and Leadership
Genomic Valley Biotech Balance Sheet Screener
Screen GVBL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹4, down from ₹4 in 2025.
Latest statistics put total assets at ₹4 and shareholder funds at ₹4.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 4 | 4 | 4 | 4 | 4 | 8 | 8 | 7 | 7 | 6 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 2 | 6 | 5 | 4 | 4 | 4 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 4 | 4 | 4 | 4 | 3 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 1 |
Genomic Valley Biotech Income Statement Screener - Profit & Revenue Analysis
Screen Genomic Valley Biotech income statement and profit fundamentals. Analyze GVBL quarterly results. Genomic Valley Biotech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹0 and net profit was ₹0, at an operating margin of 24%.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹0 and net profit of ₹0.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | 24.00% | 19.00% | 52.00% | 9.00% | 32.00% | -535.00% | -66.00% | 65.00% | 42.00% | 17.00% | -23.00% | -422.00% | -249.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 0 | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.00 | 0.10 | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 | 0.94 | 0.76 | 0.11 | -0.22 | -1.10 | -0.03 |
Genomic Valley Biotech Cash Flow Screener - Liquidity Fundamentals
Screen GVBL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹0.
Over the same period, investing activities provided ₹0 and financing activities provided ₹0.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 0 | 0 | -1 | -2 | 2 | 0 | -1 | 1 | 0 | -1 |
| Investing Activities | 0 | 0 | 2 | 4 | -2 | -1 | 0 | -1 | 0 | 1 |
Financing and Net Cash | ||||||||||
| Financing Activities | 0 | 0 | -1 | -2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Genomic Valley Biotech Shareholding Pattern Screener
See Genomic Valley Biotech shareholding pattern with promoter, FII, and DII holdings. Check Genomic Valley Biotech promoter holding and ownership changes for GVBL on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 46.06%, foreign institutions 0.00%, domestic institutions 0.00% and the public 51.01%, spread across 2,481 shareholders.
The shareholder count was 2,481 in 2026-Mar, compared with 2,448 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 46.06% | 46.06% | 46.06% | 46.78% | 46.72% | 46.72% | 46.06% | 64.20% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 51.01% | 50.82% | 50.91% | 52.62% | 52.79% | 52.53% | 52.25% | 34.45% |
| Other Holding | 2.93% | 3.12% | 3.02% | 0.60% | 0.49% | 0.76% | 1.69% | 1.35% |
| Shareholder Count | 2,481 | 2,448 | 2,430 | 2,504 | 2,460 | 2,459 | 2,522 | 1,334 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Genomic Valley Biotech. Genomic Valley Biotech dividend yield can be compared with peers and other stocks in the market.
Genomic Valley Biotech Stock Index Membership - Nifty & Sensex
See which indices include Genomic Valley Biotech stock. Check GVBL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Genomic Valley Biotech Market Events Screener - Corporate Actions
Get Genomic Valley Biotech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Genomic Valley Biotech stock events that may affect GVBL share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Annual General Meeting dated December 31, 2026, with a record date of December 31, 2026.
It is followed by Quarterly Result Announcement dated October 30, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-12-31 | 2026-12-31 | Annual General Meeting | NA | -10.30% |
| 2026-10-30 | 2026-10-30 | Quarterly Result Announcement | NA | 40.56% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | -0.96% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 0.15% |
| 2026-01-15 | 2026-01-15 | Quarterly Result Announcement | NA | -5.10% |
| 2025-12-30 | 2025-12-30 | Annual General Meeting | NA | -18.30% |
| 2025-10-15 | 2025-10-15 | Quarterly Result Announcement | NA | 0.19% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -2.15% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -11.44% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | 14.40% |
| 2024-10-07 | 2024-10-07 | Quarterly Result Announcement | NA | 0.12% |
Genomic Valley Biotech Competitors Screener - Peer Stocks Comparison
Screen GVBL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 449,180 | 40.80 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 295,586 | 87.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 177,986 | 85.00 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 122,111 | 89.90 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 119,900 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 114,426 | 41.80 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,712 | 39.50 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,928 | 47.90 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,712 | 25.80 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 90,507 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
Genomic Valley Biotech Company Announcements - News & Reports Screener
Screen GVBL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 3, 2026.
The next most recent announcements are dated November 2, 2026 and October 30, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-03 | Draft Letter of Offer | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-30 | Un-Audited Standalone Financial Results For The Quarter And Half Yearly Ended On September 30Th 2026 | - |
| 2026-10-30 | Board Meeting Outcome for Pursuant To Regulation 30 Of Sebi (LODR)Regulation 2015 Held On Today I.E. 30Th October 2026 | - |
| 2026-10-27 | Detailed Public Statement | - |
| 2026-10-21 | Board Meeting Intimation for Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |
| 2026-10-20 | Disclosure Under Regulation 30 And Regulation 30A Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI (LODR) Regulations) | - |
| 2026-10-19 | Open Offer | - |
| 2026-10-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-08-31 | Intimation Of Approval Of Extension Of Time For Holding Annual General Meeting (AGM) Of The Company For The Financial Year Ended On 31St March 2026 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Results-Financial Results For Quarter Ended On 30 June 2026. | - |
| 2026-08-14 | Board Meeting Outcome for Outcome Of The Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Held On Today I.E. 14Th August 2026 | - |
| 2026-08-06 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone) Of The Company For The Quarter Ended On June 30 2026 | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-29 | Closure of Trading Window | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | To Consider And Approve The Appointment Of Mr. Navjyoti Kumar Jha As Internal Auditor Of The Company For The F.Y. 2026-27 | - |
| 2026-05-29 | Results- Financial Results For The Quarter And Year Ended On 31 March 2026 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹44.70, within a 52-week range of ₹21.85 to ₹58.45. The P/B ratio is 3.66. Market capitalisation stands at ₹14.40 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.